Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial - Authors' reply. Al-Samkari H, B Bussel J, Miyakawa Y, Broome CM, et al. Lancet 2024;404:434.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Al-Samkari H, B Bussel J, Miyakawa Y, Broome CM, et al. Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial - Authors' reply. Lancet 2024;404:434.
PMID: 39097394